Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:binimetinib
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EE05
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mektovi
|
| gptkbp:indication |
metastatic melanoma
unresectable melanoma |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
gptkb:Array_BioPharma |
| gptkbp:mechanismOfAction |
MEK inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
gptkb:MEK1
gptkb:MEK2 |
| gptkbp:usedFor |
gptkb:Braftovi
melanoma BRAF V600E or V600K mutation-positive melanoma |
| gptkbp:bfsParent |
gptkb:Array_BioPharma
|
| gptkbp:bfsLayer |
5
|